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Abstract
Background: Revised National TB Control Programme (RNTCP), Andhra Pradesh, India. There is limited information on
whether MDR-TB suspects are identified, undergo diagnostic assessment and are initiated on treatment according to the
programme guidelines.
Objectives: To assess i) using the programme definition, the number and proportion of MDR-TB suspects in a large cohort
of TB patients on first-line treatment under RNTCP ii) the proportion of these MDR-TB suspects who underwent diagnosis for
MDR-TB and iii) the number and proportion of those diagnosed as MDR-TB who were successfully initiated on treatment.
Methods: A retrospective cohort analysis, by reviewing RNTCP records and reports, was conducted in four districts of
Andhra Pradesh, India, among patients registered for first line treatment during October 2008 to December 2009.
Results: Among 23,999 TB patients registered for treatment there were 559 (2%) MDR-TB suspects (according to
programme definition) of which 307 (55%) underwent diagnosis and amongst these 169 (55%) were found to be MDR-TB.
Of the MDR-TB patients, 112 (66%) were successfully initiated on treatment. Amongst those eligible for MDR-TB services,
significant proportions are lost during the diagnostic and treatment initiation pathway due to a variety of operational
challenges. The programme needs to urgently address these challenges for effective delivery and utilisation of the MDR-TB
services.
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Introduction
Globally, with an estimated annual incidence of more than half a
million cases, Multi-Drug Resistant-Tuberculosis (MDR-TB) i.e.
tuberculosis resistant to at least isoniazid and rifampicin, is a public
health threat [1]. The Global Stop TB Strategy outlines and defines
the programmatic management of drug resistant TB (PMDT)
within National TB Programmes based on the principles of DOTS
(Directly Observed Treatment Short Course). Timely identification
of MDR-TB cases and prompt initiation of treatment is crucial to
prevent the transmission of disease and reduce related high
morbidity and mortality [2].
MDR-TB case-finding strategies vary, depending on the local
epidemiological situation and capacity for quality assured diagnosis
and treatment. In resource rich settings, all TB patients are tested
with culture and Drug Susceptibility Testing (DST). However, in
most resource limited settings, only patients considered to have an
increased risk of MDR-TB are tested. Undiagnosed, untreated or
improperly treated patients with MDR-TB are a source of ongoing
transmission of resistant strains within the community, resulting in
future added costs and mortality [3].
In India, with the highest burden of Tuberculosis globally, the
prevalence of MDR-TB is estimated to be ,3% amongst new
cases and 14–17% amongst the re-treatment cases [4]; it is also
estimated that ,99,000 MDR-TB cases occur in the country
annually [5]. To address the challenge of MDR-TB, the Revised
National Tuberculosis Control Programme (RNTCP) of India has
initiated MDR-TB services, at a sub-national level, in 2007 in a
limited geographical area and is in the process of expanding these
services, in a phased manner, to cover the entire country by 2012.
Due to limited quality assured laboratory capacity the programme
enrols only those patients identified to be at a high risk of
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quent treatment [6].
RNTCP has limited information on the proportion of MDR-TB
suspects amongst TB patients on first line treatment within the
programme, whether all these MDR-TB suspects are identified
and undergo diagnostic assessment and whether all those
diagnosed as MDR-TB are initiated on treatment according to
the programme guidelines. We therefore decided to assess in a
large cohort of TB patients registered for first-line anti-TB
treatment i) the number and proportion who were MDR-TB
suspects according to the programme definition ii) proportion of
eligible MDR-TB suspects who underwent diagnosis (culture and
DST) for MDR-TB and iii) the number and proportion of those
diagnosed as MDR TB who were successfully initiated on MDR-
TB treatment (within the programme).
Methods
Study Setting
The state of Andhra Pradesh (AP) has a population of ,83
million with 23 administrative districts and 24 district TB control
units. The State has an RNTCP accredited Culture and DST
laboratory (Intermediate reference Laboratory), located in the
State Training and Demonstration Center (STDC) at Hyderabad
and has been performing culture and DST, using solid culture, for
first line anti-TB drugs (SRHE) since June 2008. MDR-TB
services were initiated in 4 districts of Andhra Pradesh
(Hyderabad, Rangareddy, Nalgonda and Medak) in the Phase-1
in August, 2008. This study was conducted in these four districts.
Treatment of Tuberculosis and definitions of MDR-
Suspect and MDR-TB patient under RNTCP
TB patients diagnosed under the RNTCP were categorised as
‘new’ or ‘retreatment’ cases, initiated on first line treatment and
registered in one of three categories of first line anti-TB regimens
using standard case definitions recommended by WHO treatment
guidelines [7,8]. In brief, categories I and III are used for the
treatment of ‘new’ TB cases and category II is used for the
treatment of re-treatment cases (patients who have been previously
treated with first line anti-TB drugs for at-least a month anytime in
the past).
In all the three categories, treatment is administered to patients
under the direct supervision of a DOT provider. All TB patients
initiated on treatment are registered in a ‘‘Tuberculosis Register’’
maintained in the corresponding Tuberculosis Unit (1 Tubercu-
losis Unit ,500,000 population). The Tuberculosis register is
maintained and updated by supervisory staff called the Senior
Treatment Supervisor (STS). The TB register contains the
patients’ basic demographic, clinical and treatment related
information including details of the follow-up sputum examina-
tion.
RNTCP DOTS Plus programme guidelines[6] defined an
‘MDR-TB suspect’ as: i) any TB patient who failed a category I or
category III regimen ii) any category II patient who remained
smear positive at the end of the fourth month of treatment or later,
and iii) a smear positive contact of an MDR case regardless of
prior anti-TB treatment. Patients who met this definition of MDR-
TB suspect were to be identified and offered diagnostic services for
MDR- TB as shown in Figure 1. The District TB Officer (DTO)
is responsible for maintaining all the patient records and registers
through RNTCP staff available at the DTC. The sputum is
transported from the DMC to IRL under information to the
DTO. The DTO also verifies from the previous treatment records
whether the patient fulfils the criteria of MDR suspect.
Study design, Study Population and sample size
The design was a retrospective record review study. All patients
registered for treatment with first line anti-tuberculosis treatment
during the period October 2008 to December 2009 within
RNTCP in the four Phase-1 districts implementing DOTS-plus
Figure 1. Diagnostic and treatment initiation pathway for Multi-drug resistant TB (MDR- TB) under RNTCP.
doi:10.1371/journal.pone.0026659.g001
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and Medak) were included in the study. This cohort included
23,999 patients with all forms of TB. The study was conducted in
the month of February, 2011.
Study variables and sources of data
Data variables and their source (within brackets) were: Number
of TB patients registered (TB Register), their date of registration
(TB Register), type of TB (TB Register), sputum smear status (TB
Register), the results of follow-up sputum smear status (TB
Register) and treatment outcomes (TB Register), number of
MDR suspects (TB Register), number of MDR suspects referred
for culture and DST (TB Register and Referral for culture and
DST Register), number of MDR suspects diagnosed as MDR-TB
(Culture and DST Register at the accredited laboratory), number
of diagnosed MDR cases initiated on treatment (DOTS Plus TB
Register maintained at the DOTS Plus site). .
Data management and statistical analysis
Data from relevant records was extracted to a pre-structured
questionnaire independently by two study investigators, cross
checked for consistency, and all discrepancies were resolved by
referring to the original records. Data was entered and analysed
using Epidata statistical software package (version 3.1). Propor-
tions have been used to summarise the various variables.
Ethics
This study was a record review of routinely collected
programme surveillance data for which approval from the Central
TB Division, Ministry of Health and Family Welfare, Govt. of
India and the State TB Cell, Directorate of Health Services,
Government of Andhra Pradesh was obtained. The study protocol
was also reviewed and approved by the Ethics Advisory Group of
the International Union against Tuberculosis and Lung Disease.
Results
There were 559 (2%) MDR-TB suspects (program defined)
among 23,999 TB patients registered for treatment during the
study period. For each of the five quarters under the study period
(Oct 2008 to Dec 2009), the proportion of MDR-TB suspects
amongst TB patients was almost similar varying from 2.0% to
3.0% (Table 1). The characteristics of these MDR-TB suspects is
given in Table 2
Out of 559 MDR-TB suspects, sputum was collected and
transported from the periphery to the culture and DST laboratory
in 387 (69%) cases of which 360 (93%) were received at the
laboratory. The culture results were available for 307 (85%) of
which DST results were available in 265 (86%). Among these 265
cases, 169 (64%) were diagnosed as MDR-TB. Of these 169
patients, 112 (66%) of the patients were initiated on MDR-TB
treatment regimen under RNTCP. The flow of patients and the
reasons for loss of patients at each step in the process of diagnosis
and initiation of treatment is shown in Figure 2.
Overall, out of the 559 MDR-TB suspects, 307 (55%)
underwent diagnosis for MDR-TB. 169 patients were diagnosed
as MDR-TB of which 112 (66%) were initiated on MDR-TB
treatment.
Discussion
This is the first study which describes the flow of MDR-TB
suspects along the diagnostic and treatment initiation pathway
under RNTCP. About 2% of a large cohort of TB patients was
classified as MDR-TB suspects, and this was similar in each of the
five quarterly cohorts analysed. There was a fall off of patients at
each stage of the referral and diagnostic process, resulting in only
one third of MDR-TB suspects (programme defined) being
diagnosed with MDR-TB and only 66% of diagnosed patients
initiating treatment.
The study was operational in nature and relied on a review of
registers in various locations. This study identifies three major
operational challenges that are programmatically relevant and
have had important programmatic implications.
The first is the significant patient loss during and after
identification as MDR-TB suspects. It was observed that a
significant number of MDR-TB suspects miss identification by
the programme staff which calls for appropriate training and more
intensive supervision. In some instances the programme staffs were
line listing the suspects but this was not uniformly practiced. A
fourth of the identified MDR-TB suspects refused to undergo
Table 1. Multi-drug resistant TB (MDR-TB) suspects (as per
RNTCP definition) in a cohort of patients in Andhra Pradesh.
Cohort
Number registered
(n)
Number of MDR suspects
(n) (%)
Oct–Dec 2008 4472 98 2.2
Jan–Mar 2009 4824 143 3.0
Apr–Jun 2009 5332 108 2.0
Jul–Sep 2009 4709 116 2.5
Oct–Dec 2009 4662 94 2.0
Total 23999 559 2.0
doi:10.1371/journal.pone.0026659.t001
Table 2. Characteristics of MDR-TB suspects in a cohort of
patients in Andhra Pradesh (N=559).
Characteristic N (%)
Gender
Male 410 73
Female 149 27
Age group
,15 Years 14 (3)
15–24 years 113 (20)
25–34 years 132 (24)
35–44 years 128 (23)
45–54 years 106 (19)
55–64 years 57 (10)
.64 years 7 (1)
Treatment category
Cat-1 217 (39)
Cat-2 331 (59)
Cat-3 11 (2)
Status of HIV
Negative 407 (73)
Positive 37 (7)
Unknown 115 (21)
doi:10.1371/journal.pone.0026659.t002
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motivation which is presently missing in the programme. Proper
address verification and repeated retrieval efforts will help in
reducing the number of patients who could not be traced. Deaths
can be prevented in this group through steps taken to ensure early
identification and diagnosis which may require a change in the
existing criteria of failing a first line regimen to be eligible as a
MDR-TB suspect to all TB patients who continue to be smear
positive during follow up and finally to all TB patients on initiation
of treatment. This will also require a rapid scale up of the
laboratory capacity across the country.
The second is the loss in number of samples for which culture
result should have been available. There is a need for an efficient
and secure system to prevent loss during transportation. The high
rates of contamination and culture negativity requires better
collection of sputum samples and more robust laboratory
procedures. Adoption of new molecular technologies like Line
Probe Assay (LPA) and Nucleic Acid Amplification tests (NAAT)
[9] which preclude the need for culture will also help in rapid
diagnosis and avoid this loss.
The third is to ensure initiation of treatment for all diagnosed
MDR-TB patients. In our present study, the extent of this loss was
34% attributable primarily to refusal for treatment (including
those who had initiated treatment outside the programme). This
could be due to the long delay in the availability of results, inability
to travel to distantly located DOTS Plus sites for pre-treatment
evaluation. This reiterates the need for deployment of rapid
diagnostics and decentralisation of centres where treatment can be
initiated. This will also help in early initiation of treatment which
will prevent significant number of deaths in this group.
These three operational challenges are likely to be encountered
by most TB control programmes in low and middle income
countries that are initiating MDR-TB treatment services. Such
challenges have also been noted in China [10] and these
challenges are a result of not having decentralised rapid diagnostic
and treatment initiation facilities. Care must be taken to ensure
that the loss of patients is minimised by instituting adequate
programmatic mechanisms.
In order to address these challenges RNTCP has instituted a
series of corrective programmatic mechanisms. This includes
formulating programme guideline that all sputum specimens
should reach the designated culture and DST laboratory within 2
weeks of the patient being identified as an MDR-TB suspect and
assigning the responsibility of monitoring this activity by a
dedicated supervisor. This has resulted in instituting a mechanism
for collection of sputum specimens as soon as the follow-up sputum
smears are found positive at the DMC and are provided to the
patient thus ensuring that they are transported within the
stipulated time by a dedicated transportation mechanism. In
order to reduce the time duration between receipt of specimens at
Figure 2. Loss of MDR-TB suspects along the diagnostic and treatment initiation pathway under RNTCP in Andhra Pradesh.
doi:10.1371/journal.pone.0026659.g002
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programme is introducing newer rapid diagnostic technology such
as LPA in place of solid culture and DST. For patients who refuse
MDR treatment primarily due to inability to travel to DOTS Plus
sites, usually located at large distances, for pre-treatment
evaluation and treatment initiation the programme provides
incentives to cover the cost of the travel of the patient and one
attendant. In addition, there is a provision for initiating treatment
at the district level where facilities exist for pre-treatment
evaluation. This study also provides baseline information that
can be compared with results from subsequent changes in
programme design or definitions. In addition, the RNTCP is also
undertaking intensive and follow up trainings of the staff on
identification of MDR-TB suspects and counselling of patients to
prevent drop out at various stages.
Limitations of the study
The study being retrospective in nature and has its inherent
limitations of record review studies. If the records maintained at
various levels were not updated periodically or were incorrect for
any reason, then this has the potential to affect the study results.
The programme is however, supervised and monitored regularly
from various staff and includes periodic data validation, hence the
likelihood of any recording errors are minimal [11]. Secondly, in
order to fully understand the operational challenges, both provider
and patient perspectives are needed. This study however provides
information on the operational aspects from the programme
perspective and not from the patient perspective.
Conclusion
In a cohort of TB patients in one of the sites in India, there were
2% MDR-TB suspects (programme defined), about 70% of these
underwent diagnosis, 30% were found to be MDR-TB of which
66% were initiated on MDR-TB treatment. There is an urgent
need to ensure that operational challenges that are resulting in the
loss of patients during the MDR-TB diagnostic and treatment
pathway are adequately addressed by corrective mechanisms
initiated by national programmes.
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